Compare Fox Corp Class B (FOX) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Novo Nordisk A/S — how do they compare? Fox Corp Class B trades at $55.53 (market cap $24.58B), while Novo Nordisk A/S trades at $46.23 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 8.5× Fox Corp Class B's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| FOX | NVO | |
|---|---|---|
Market Cap | $24.58B | $207.85B |
Sector | Media | Health |
52-Week High | $67.76 | $63.98 |
52-Week Low | $44.39 | $35.29 |
Enterprise Value | $27.94B | $222.55B |
Dividend Yield | 1.05% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX trades at $55.32, down 1.79% on the day, with a bullish technical outlook supported by moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.79 exceeding the $1.44 estimate, and revenue growth to $16.30 billion in 2025. A dividend of $0.29 is scheduled for September 2026, reflecting financial health. Analyst sentiment is mixed but leans positive, with 42.86% recommending buy.
The outlook for FOX is favorable, driven by digital growth and advertising momentum, though risks include competitive pressures and potential economic volatility. The stock's valuation metrics, including a P/E of 14.41, suggest reasonable pricing relative to earnings, supporting a cautious optimism for investors seeking exposure to media and entertainment sectors.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
